Addendum

Dapagliflozin (kidney disease) - Addendum to Commission A21-109

Report documents

Indication:

Adults with chronic kidney disease

Result of dossier assessment:

Unchanged after addendum:

Without symptomatic chronic heart failure as comorbidity: hint of considerable added benefit
With additional symptomatic chronic heart failure as comorbidity: hint of non-quantifiable added benefit

2022-02-18 A G-BA decision was published.

Project no.: A22-02
Commission: Commission awarded on 11.01.2022 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Kidneys and urinary system
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.